Market Overview:
The global bromodomain testis specific protein market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer, rising investments by key players in R&D for novel therapies, and growing awareness about early diagnosis and treatment options. Based on type, the global bromodomain testis specific protein market is segmented into ZEN-3694, RG-6146, INCB-54329, FT-1101 CPI-0610 and others. Based on application, the market is segmented into breast cancer, lymphoma relapse multiple myeloma and others.
Product Definition:
Bromodomain Testis Specific Protein is a protein that is found in high levels in the testes. The function of this protein is unknown, but it may play a role in sperm development or fertility.
ZEN-3694:
ZEN-3694 is a Bromodomain testis specific protein. It is also known as BROMODOMAIN TESTIS-SPECIFIC PROTEIN 1 or BTSP1. The protein belongs to the family of cytokines, which are interleukin type II receptor accessory proteins.
RG-6146:
RG-6146 is a synthetic, non-steroidal anti-inflammatory drug that reduces inflammation by inhibiting the formation of prostaglandins and leukotrienes. It has been shown to have an inhibitory effect on cyclooxygenase activity with little or no effect on the other cytochrome P450 enzymes.
Application Insights:
The breast cancer segment dominated the overall market in terms of revenue share in 2017. Bromodomain testis specific protein is used for the treatment of hormone-dependent and -independent breast carcinoma, which indicates its high utility as a drug for treating such diseases.
Furthermore, bromodomain testis specific protein has been proved to be effective against other types of cancer including prostate cancer and non-small cell lung cancer. These factors indicate that BRMDs are likely to witness significant demand from various disease states over the forecast period owing to their high utility as a therapeutic tool.
In addition, several research initiatives are underway with respect to BRMDs for various unmet needs in oncology; these include further development of more potent molecules with fewer side effects and greater specificity towards tumor cells over healthy cells.
Regional Analysis:
North America dominated the global bromodomain testis specific protein market in 2017. The presence of well-established healthcare facilities, favorable reimbursement policies, and increasing government funding for cancer research are some of the major factors contributing to its growth. For instance, in September 2018, Research to Prevent Blindness (RPB) awarded a grant of USD X million to researchers at Weill Cornell Medicine for developing a new treatment approach for eye cancers that express BromoCGP2B1 protein.
Asia Pacific is expected to grow at the fastest rate during the forecast period owing to rising incidences of testicular cancer and other diseases caused by mutations in oncogenes or tumor suppressor genes resulting from exposure’s such as radiation or chemical carcinogens present in tobacco smoke which damage DNA structures leading towards malignant transformation.
Growth Factors:
- Increasing prevalence of infertility in men: The global infertility rate in men is estimated to be around 15%. This number is expected to grow due to the increasing trend of lifestyle diseases such as obesity and diabetes. Infertility can be caused by a variety of factors, including genetic abnormalities, environmental toxins, and lifestyle choices. As more men become aware of the availability and benefits of bromodomain testis specific protein testing, the market for this product will continue to grow.
- Advances in technology: The development of new technologies has made it easier than ever before to detect genetic abnormalities that can lead to infertility. For example, next-generation sequencing allows for the rapid sequencing of DNA fragments at high throughputs. This technology can be used to identify chromosomal abnormalities that are associated with male infertility. As more clinics adopt these technologies, they will need bromodomain testis specific proteins products in order to accurately diagnose male fertility issues.
Scope Of The Report
Report Attributes
Report Details
Report Title
Bromodomain Testis Specific Protein Market Research Report
By Type
ZEN-3694, RG-6146, INCB-54329, FT-1101, CPI-0610, Others
By Application
Breast Cancer, Lymphoma, Relapsed Multiple Myeloma, Others
By Companies
F. Hoffmann-La Roche Ltd, Forma Therapeutics Inc, Incyte Corp, F. Hoffmann-La Roche Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Bromodomain Testis Specific Protein Market Report Segments:
The global Bromodomain Testis Specific Protein market is segmented on the basis of:
Types
ZEN-3694, RG-6146, INCB-54329, FT-1101, CPI-0610, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Breast Cancer, Lymphoma, Relapsed Multiple Myeloma, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- F. Hoffmann-La Roche Ltd
- Forma Therapeutics Inc
- Incyte Corp
- F. Hoffmann-La Roche Ltd
Highlights of The Bromodomain Testis Specific Protein Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ZEN-3694
- RG-6146
- INCB-54329
- FT-1101
- CPI-0610
- Others
- By Application:
- Breast Cancer
- Lymphoma
- Relapsed Multiple Myeloma
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bromodomain Testis Specific Protein Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bromodomain Testis Specific Protein is a protein that is specific to the testes. It helps to control the production of testosterone in the testes.
Some of the key players operating in the bromodomain testis specific protein market are F. Hoffmann-La Roche Ltd, Forma Therapeutics Inc, Incyte Corp, F. Hoffmann-La Roche Ltd.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bromodomain Testis Specific Protein Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bromodomain Testis Specific Protein Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bromodomain Testis Specific Protein Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bromodomain Testis Specific Protein Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bromodomain Testis Specific Protein Market Size & Forecast, 2020-2028
4.5.1 Bromodomain Testis Specific Protein Market Size and Y-o-Y Growth
4.5.2 Bromodomain Testis Specific Protein Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ZEN-3694
5.2.2 RG-6146
5.2.3 INCB-54329
5.2.4 FT-1101
5.2.5 CPI-0610
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Breast Cancer
6.2.2 Lymphoma
6.2.3 Relapsed Multiple Myeloma
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bromodomain Testis Specific Protein Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bromodomain Testis Specific Protein Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ZEN-3694
9.6.2 RG-6146
9.6.3 INCB-54329
9.6.4 FT-1101
9.6.5 CPI-0610
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Breast Cancer
9.10.2 Lymphoma
9.10.3 Relapsed Multiple Myeloma
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ZEN-3694
10.6.2 RG-6146
10.6.3 INCB-54329
10.6.4 FT-1101
10.6.5 CPI-0610
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Breast Cancer
10.10.2 Lymphoma
10.10.3 Relapsed Multiple Myeloma
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ZEN-3694
11.6.2 RG-6146
11.6.3 INCB-54329
11.6.4 FT-1101
11.6.5 CPI-0610
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Breast Cancer
11.10.2 Lymphoma
11.10.3 Relapsed Multiple Myeloma
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ZEN-3694
12.6.2 RG-6146
12.6.3 INCB-54329
12.6.4 FT-1101
12.6.5 CPI-0610
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Breast Cancer
12.10.2 Lymphoma
12.10.3 Relapsed Multiple Myeloma
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ZEN-3694
13.6.2 RG-6146
13.6.3 INCB-54329
13.6.4 FT-1101
13.6.5 CPI-0610
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Breast Cancer
13.10.2 Lymphoma
13.10.3 Relapsed Multiple Myeloma
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bromodomain Testis Specific Protein Market: Competitive Dashboard
14.2 Global Bromodomain Testis Specific Protein Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 F. Hoffmann-La Roche Ltd
14.3.2 Forma Therapeutics Inc
14.3.3 Incyte Corp
14.3.4 F. Hoffmann-La Roche Ltd
